ClinicalTrials.gg
CompletedNCT00553475Updated Jan 25, 2021Results posted

Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3 interventional study of placebo and pregabalin in Diabetic Neuropathy, Painful, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 49 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.

Enrollment
8th of 17
314 · median 241
Started
2007
with 1 other
Phase 3
10 of 17
1 open now
Registered
7th of 17
by date
Lead sponsor
9 of 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 8th largest by enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 7th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pregabalin in Diabetic Neuropathies, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.

03

Conditions studied

  • Diabetic Neuropathy, Painful

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual Analogue Scale (VAS) of pain is higher than 40 mm.
  • Diagnosis of type 1 or 2 diabetes mellitus for at least 1 year

Exclusion criteria

Exclusion Criteria:

  • within the past 2 years.
  • Neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathy pain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
314 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: placebo

  • Experimental
    Pregabalin 300 mg/day

    Drug: pregabalin

  • Experimental
    Pregabalin 600 mg/day

    Drug: pregabalin

Interventions

  • Drugplacebo

    Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)

  • Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)

  • Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Study Endpoint in Mean Weekly Pain Scores

    Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  2. Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations

    Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  3. Number of Responders

    A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  4. Change From Baseline at Week 1 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1. Change from baseline: Score at Week 1 minus score at baseline

    Time frame: From baseline to Week 1

  5. Change From Baseline at Week 2 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2. Change from baseline: Score at Week 2 minus score at baseline

    Time frame: From baseline to Week 2

  6. Change From Baseline at Week 3 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3. Change from baseline: Score at Week 3 minus score at baseline

    Time frame: From baseline to Week 3

  7. Change From Baseline at Week 4 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4. Change from baseline: Score at Week 4 minus score at baseline

    Time frame: From baseline to Week 4

  8. Change From Baseline at Week 5 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5. Change from baseline: Score at Week 5 minus score at baseline

    Time frame: From baseline to Week 5

  9. Change From Baseline at Week 6 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6. Change from baseline: Score at Week 6 minus score at baseline

    Time frame: From baseline to Week 6

  10. Change From Baseline at Week 7 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7. Change from baseline: Score at Week 7 minus score at baseline

    Time frame: From baseline to Week 7

  11. Change From Baseline at Week 8 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8. Change from baseline: Score at Week 8 minus score at baseline

    Time frame: From baseline to Week 8

  12. Change From Baseline at Week 9 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9. Change from baseline: Score at Week 9 minus score at baseline

    Time frame: From baseline to Week 9

  13. Change From Baseline at Week 10 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10. Change from baseline: Score at Week 10 minus score at baseline

    Time frame: From baseline to Week 10

  14. Change From Baseline at Week 11 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11. Change from baseline: Score at Week 11 minus score at baseline

    Time frame: From baseline to Week 11

  15. Change From Baseline at Week 12 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12. Change from baseline: Score at Week 12 minus score at baseline

    Time frame: From baseline to Week 12

  16. Change From Baseline at Week 13 in Mean Weekly Pain Scores

    The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13. Change from baseline: Score at Week 13 minus score at baseline

    Time frame: From baseline to Week 13

Secondary outcomes

  1. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  2. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  3. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  4. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  5. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  6. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  7. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  8. Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health

    The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  9. Change From Baseline in Mean Sleep Interference Scores

    The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  10. Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  11. Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  12. Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  13. Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  14. Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  15. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  16. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  17. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  18. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  19. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  20. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  21. Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index

    The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.

    Time frame: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

  22. Clinical Global Impression of Change

    Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 13 or up to discontinuation

  23. Patient Global Impression of Change

    The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 13 or up to discontinuation

07

Results

Posted Jun 22, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Started13513445
Completed11911432
Not completed162013
Withdrew: Adverse event71713
Withdrew: Lack of efficacy710
Withdrew: Withdrawal by subject110
Withdrew: Physician decision100
Withdrew: Due to moving010

Outcome measures

PrimaryChange From Baseline to Study Endpoint in Mean Weekly Pain Scores

Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores-1.20 ± 0.21-1.82 ± 0.22-1.94 ± 0.32
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0075 · Mean difference (final values): -0.63 · 95% CI -1.09 to -0.17Treatment groups and the CLcr strata as factors and baseline values as covariates.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0254 · Mean difference (final values): -0.74 · 95% CI -1.39 to -0.09Treatment groups and the CLcr strata as factors and baseline values as covariates.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning2.70 ± 1.582.43 ± 1.593.86 ± 2.33
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.8731 · Mean difference (final values): -0.28 · 95% CI -3.67 to 3.12The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.6337 · Mean difference (final values): 1.16 · 95% CI -3.62 to 5.94The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical4.38 ± 2.472.28 ± 2.503.97 ± 3.70
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.4398 · Mean difference (final values): -2.10 · 95% CI -7.44 to 3.24The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.9153 · Mean difference (final values): -0.41 · 95% CI -7.96 to 7.14The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain10.34 ± 1.9711.84 ± 1.9912.89 ± 2.91
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.4873 · Mean difference (final values): 1.50 · 95% CI -2.75 to 5.76The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.4008 · Mean difference (final values): 2.56 · 95% CI -3.42 to 8.53The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception2.31 ± 1.443.29 ± 1.454.40 ± 2.14
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.5372 · Mean difference (final values): 0.98 · 95% CI -2.13 to 4.09The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.3480 · Mean difference (final values): 2.09 · 95% CI -2.29 to 6.47The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning3.00 ± 2.398.06 ± 2.4111.16 ± 3.54
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0544 · Mean difference (final values): 5.06 · 95% CI -0.10 to 10.21The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0278 · Mean difference (final values): 8.15 · 95% CI 0.89 to 15.42The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional4.13 ± 2.525.05 ± 2.556.35 ± 3.77
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.7394 · Mean difference (final values): 0.92 · 95% CI -4.52 to 6.37The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.5712 · Mean difference (final values): 2.22 · 95% CI -5.49 to 9.93The model included treatment and CLcr stratum as factors, and baseline score as covariate.
PrimaryChange From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations

Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr).

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations
score on scalePlaceboExpected Exposure Pregabalin 300 mg/DayExpected Exposure Pregabalin 600 mg/Day
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations-1.27 ± 0.16-1.93 ± 0.17-1.90 ± 0.25
Statistical analysis
  • Placebo vs Expected Exposure Pregabalin 300 mg/Day · ANCOVA · p = 0.0058 · Mean difference (final values): -0.67 · 95% CI -1.14 to -0.19Treatment groups as factors and baseline values as covariates
  • Placebo vs Expected Exposure Pregabalin 600 mg/Day · ANCOVA · p = 0.0333 · Mean difference (final values): -0.64 · 95% CI -1.23 to -0.05Treatment groups as factors and baseline values as covariates
PrimaryNumber of Responders

A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Number · participants
Number of Responders
participantsPlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Number of Responders293916
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Cochran-Mantel-Haenszel · p = 0.153stratified by CLcr stratum
  • Placebo vs Pregabalin 600 mg/Day · Cochran-Mantel-Haenszel · p = 0.059stratified by CLcr stratum
PrimaryChange From Baseline at Week 1 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1. Change from baseline: Score at Week 1 minus score at baseline

Time frame:
From baseline to Week 1
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 1 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 1 in Mean Weekly Pain Scores-0.39 ± 0.17-0.82 ± 0.17-1.14 ± 0.26
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0287 · Mean difference (final values): -0.43 · 95% CI -0.82 to -0.05Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0073 · Median difference (final values): -0.75 · 95% CI -1.29 to -0.20Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 2 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2. Change from baseline: Score at Week 2 minus score at baseline

Time frame:
From baseline to Week 2
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 2 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 2 in Mean Weekly Pain Scores-0.57 ± 0.17-1.17 ± 0.17-1.80 ± 0.26
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0021 · Mean difference (final values): -0.61 · 95% CI -1.00 to -0.22Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = <0.0001 · Mean difference (final values): -1.23 · 95% CI -1.78 to -0.69Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 3 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3. Change from baseline: Score at Week 3 minus score at baseline

Time frame:
From baseline to Week 3
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 3 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 3 in Mean Weekly Pain Scores-0.80 ± 0.17-1.40 ± 0.17-1.93 ± 0.26
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0026 · Mean difference (final values): -0.60 · 95% CI -0.99 to -0.21Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = <0.0001 · Mean difference (final values): -1.13 · 95% CI -1.69 to -0.58Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 4 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4. Change from baseline: Score at Week 4 minus score at baseline

Time frame:
From baseline to Week 4
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 4 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 4 in Mean Weekly Pain Scores-0.89 ± 0.17-1.53 ± 0.17-2.00 ± 0.26
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0012 · Mean difference (final values): -0.64 · 95% CI -1.03 to -0.25Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = <0.0001 · Mean difference (final values): -1.11 · 95% CI -1.67 to -0.56Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 5 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5. Change from baseline: Score at Week 5 minus score at baseline

Time frame:
From baseline to Week 5
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 5 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 5 in Mean Weekly Pain Scores-0.91 ± 0.17-1.57 ± 0.17-2.07 ± 0.27
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0011 · Mean difference (final values): -0.65 · 95% CI -1.04 to -0.26Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = <0.0001 · Mean difference (final values): -1.16 · 95% CI -1.72 to -0.60Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 6 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6. Change from baseline: Score at Week 6 minus score at baseline

Time frame:
From baseline to Week 6
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 6 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 6 in Mean Weekly Pain Scores-0.94 ± 0.17-1.72 ± 0.17-2.06 ± 0.27
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = <0.0001 · Mean difference (final values): -0.79 · 95% CI -1.18 to -0.40Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = <0.0001 · Mean difference (final values): -1.12 · 95% CI -1.68 to -0.56Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 7 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7. Change from baseline: Score at Week 7 minus score at baseline

Time frame:
From baseline to Week 7
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 7 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 7 in Mean Weekly Pain Scores-1.04 ± 0.17-1.76 ± 0.17-2.13 ± 0.27
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0003 · Mean difference (final values): -0.72 · 95% CI -1.12 to -0.33Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0002 · Mean difference (final values): -1.09 · 95% CI -1.66 to -0.52Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 8 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8. Change from baseline: Score at Week 8 minus score at baseline

Time frame:
From baseline to Week 8
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 8 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 8 in Mean Weekly Pain Scores-1.18 ± 0.17-1.85 ± 0.17-2.12 ± 0.27
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0008 · Mean difference (final values): -0.67 · 95% CI -1.07 to -0.28Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0014 · Mean difference (final values): -0.94 · 95% CI -1.51 to -0.36Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 9 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9. Change from baseline: Score at Week 9 minus score at baseline

Time frame:
From baseline to Week 9
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 9 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 9 in Mean Weekly Pain Scores-1.20 ± 0.17-1.93 ± 0.17-2.06 ± 0.28
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0003 · Mean difference (final values): -0.73 · 95% CI -1.12 to -0.33Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0036 · Mean difference (final values): -0.86 · 95% CI -1.44 to -0.28Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 10 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10. Change from baseline: Score at Week 10 minus score at baseline

Time frame:
From baseline to Week 10
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 10 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 10 in Mean Weekly Pain Scores-1.23 ± 0.17-1.93 ± 0.18-2.10 ± 0.28
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0005 · Mean difference (final values): -0.70 · 95% CI -1.10 to -0.31Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0034 · Mean difference (final values): -0.87 · 95% CI -1.46 to -0.29Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 11 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11. Change from baseline: Score at Week 11 minus score at baseline

Time frame:
From baseline to Week 11
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 11 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 11 in Mean Weekly Pain Scores-1.32 ± 0.17-1.95 ± 0.18-2.09 ± 0.28
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0023 · Mean difference (final values): -0.62 · 95% CI -1.02 to -0.22Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0105 · Mean difference (final values): -0.77 · 95% CI -1.36 to -0.18Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
PrimaryChange From Baseline at Week 12 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12. Change from baseline: Score at Week 12 minus score at baseline

Time frame:
From baseline to Week 12
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 12 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 12 in Mean Weekly Pain Scores-1.36 ± 0.17-2.01 ± 0.18-2.13 ± 0.29
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0016 · Mean difference (final values): -0.65 · 95% CI -1.05 to -0.25Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0111 · Mean difference (final values): -0.77 · 95% CI -1.37 to -0.18Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality5.28 ± 1.924.20 ± 1.9412.87 ± 2.84
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.6118 · Mean difference (final values): -1.07 · 95% CI -5.23 to 3.08The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0109 · Mean difference (final values): 7.59 · 95% CI 1.76 to 13.42The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health3.84 ± 1.835.33 ± 1.857.81 ± 2.72
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.4602 · Mean difference (final values): 1.49 · 95% CI -2.47 to 5.45The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.1625 · Mean difference (final values): 3.97 · 95% CI -1.61 to 9.54The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Mean Sleep Interference Scores

The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Mean Sleep Interference Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Mean Sleep Interference Scores-0.74 ± 0.18-1.59 ± 0.18-1.36 ± 0.27
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = <0.0001 · Mean difference (final values): -0.85 · 95% CI -1.25 to -0.46The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0273 · Mean difference (final values): -0.63 · 95% CI -1.19 to -0.07The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores-2.82 ± 0.50-4.60 ± 0.50-4.95 ± 0.74
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0013 · Mean difference (final values): -1.79 · 95% CI -2.87 to -0.71The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0062 · Mean difference (final values): -2.13 · 95% CI -3.65 to -0.61The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores-0.83 ± 0.20-1.43 ± 0.20-1.39 ± 0.30
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0068 · Mean difference (final values): -0.60 · 95% CI -1.03 to -0.17The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0707 · Mean difference (final values): -0.56 · 95% CI -1.17 to 0.05The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Total Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores-3.68 ± 0.66-6.03 ± 0.66-6.36 ± 0.97
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0013 · Mean difference (final values): -2.35 · 95% CI -3.76 to -0.93The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0087 · Mean difference (final values): -2.67 · 95% CI -4.67 to -0.68The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · mm
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores
mmPlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores-16.92 ± 2.38-24.19 ± 2.40-24.41 ± 3.53
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0056 · Mean difference (final values): -7.27 · 95% CI -12.40 to -2.14The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0427 · Mean difference (final values): -7.49 · 95% CI -14.74 to -0.25The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores-0.59 ± 0.09-0.80 ± 0.09-0.96 ± 0.13
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0365 · Mean difference (final values): -0.21 · 95% CI -0.40 to -0.01The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0073 · Mean difference (final values): -0.37 · 95% CI -0.65 to -0.10The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance-9.03 ± 1.86-15.40 ± 1.88-12.81 ± 2.77
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0019 · Mean difference (final values): -6.37 · 95% CI -10.38 to -2.36The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.1907 · Mean difference (final values): -3.78 · 95% CI -9.45 to 1.89The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring-6.00 ± 2.51-5.96 ± 2.53-1.56 ± 3.71
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.9905 · Mean difference (final values): 0.03 · 95% CI -5.37 to 5.43The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.2532 · Mean difference (final values): 4.44 · 95% CI -3.19 to 12.08The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache-1.63 ± 1.69-3.02 ± 1.71-4.47 ± 2.51
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.4538 · Mean difference (final values): -1.39 · 95% CI -5.05 to 2.26The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.2782 · Mean difference (final values): -2.84 · 95% CI -7.97 to 2.30The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep0.37 ± 0.120.69 ± 0.120.54 ± 0.18
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0177 · Mean difference (final values): 0.32 · 95% CI 0.06 to 0.59The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.3661 · Mean difference (final values): 0.17 · 95% CI -0.20 to 0.55The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy12.08 ± 2.6117.69 ± 2.6421.73 ± 3.87
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0511 · Mean difference (final values): 5.62 · 95% CI -0.03 to 11.26The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0173 · Mean difference (final values): 9.65 · 95% CI 1.72 to 17.59The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence-2.96 ± 2.170.83 ± 2.194.83 ± 3.20
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.1123 · Mean difference (final values): 3.79 · 95% CI -0.89 to 8.47The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.0206 · Mean difference (final values): 7.79 · 95% CI 1.20 to 14.38The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryChange From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute.

Time frame:
From baseline to Week 13 or up to study discontinuation (Study Endpoint)
Reported as:
Least squares mean · score on scale
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index-7.91 ± 1.45-11.45 ± 1.46-9.73 ± 2.16
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · ANCOVA · p = 0.0269 · Mean difference (final values): -3.54 · 95% CI -6.67 to -0.41The model included treatment and CLcr stratum as factors, and baseline score as covariate.
  • Placebo vs Pregabalin 600 mg/Day · ANCOVA · p = 0.4183 · Mean difference (final values): -1.82 · 95% CI -6.24 to 2.60The model included treatment and CLcr stratum as factors, and baseline score as covariate.
SecondaryClinical Global Impression of Change

Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 13 or up to discontinuation
Reported as:
Mean · score on scale
Clinical Global Impression of Change
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Clinical Global Impression of Change3.3 ± 1.22.9 ± 1.12.7 ± 1.1
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Cochran-Mantel-Haenszel · p = 0.0148Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr
  • Placebo vs Pregabalin 600 mg/Day · Cochran-Mantel-Haenszel · p = 0.0063Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr
SecondaryPatient Global Impression of Change

The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 13 or up to discontinuation
Reported as:
Mean · score on scale
Patient Global Impression of Change
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Patient Global Impression of Change3.4 ± 1.33.2 ± 1.02.8 ± 1.0
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Cochran-Mantel-Haenszel · p = 0.0818Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr
  • Placebo vs Pregabalin 600 mg/Day · Cochran-Mantel-Haenszel · p = 0.0075Cochran-Mantel-Haenszel chi-squared with a modified ridit transformation, stratified by stratum based on the CLcr
PrimaryChange From Baseline at Week 13 in Mean Weekly Pain Scores

The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13. Change from baseline: Score at Week 13 minus score at baseline

Time frame:
From baseline to Week 13
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 13 in Mean Weekly Pain Scores
score on scalePlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
Change From Baseline at Week 13 in Mean Weekly Pain Scores-1.38 ± 0.17-2.04 ± 0.18-2.12 ± 0.29
Statistical analysis
  • Placebo vs Pregabalin 300 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0013 · Mean difference (final values): -0.66 · 95% CI -1.07 to -0.26Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.
  • Placebo vs Pregabalin 600 mg/Day · Mixed Model Repeated Measures Analysis · p = 0.0152 · Mean difference (final values): -0.74 · 95% CI -1.34 to -0.14Model included treatment, CLcr stratum, week and treatment-by-week interaction, and baseline scores as fixed effects, and subject as a random effect.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/135 (2.2%)50/135 (37%)
Pregabalin 300 mg/Day—2/134 (1.5%)71/134 (53%)
Pregabalin 600 mg/Day—1/45 (2.2%)36/45 (80%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
DehydrationMetabolism and nutrition disorders0/1350/1341/45
HypoglycaemiaMetabolism and nutrition disorders0/1350/1341/45
PyrexiaGeneral disorders0/1351/1340/45
Brain stem infarctionNervous system disorders0/1351/1340/45
Hypertensive encephalopathyNervous system disorders0/1351/1340/45
Atrial fibrillationCardiac disorders1/1350/1340/45
NauseaGastrointestinal disorders1/1350/1340/45
Feeling abnormalGeneral disorders1/1350/1340/45
Peripheral coldnessGeneral disorders1/1350/1340/45
Herpes zosterInfections and infestations1/1350/1340/45
Most frequent other events
Most frequent other events
EventPlaceboPregabalin 300 mg/DayPregabalin 600 mg/Day
DizzinessNervous system disorders9/13526/13418/45
SomnolenceNervous system disorders12/13528/13418/45
Oedema peripheralGeneral disorders8/13519/1348/45
Weight increasedInvestigations5/13517/1347/45
NasopharyngitisInfections and infestations20/13516/1344/45
ConstipationGastrointestinal disorders1/1354/1343/45
DiarrhoeaGastrointestinal disorders5/1353/1343/45
OedemaGeneral disorders1/1354/1343/45

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboPregabalin 300 mg/DayPregabalin 600 mg/DayTotal
< 18 years0000
18 - 44 years78116
45 - 64 years767825179
>= 65 years524819119
Age, Continuous
Age, Continuous(years)PlaceboPregabalin 300 mg/DayPregabalin 600 mg/DayTotal
Mean61.3 ± 9.661.3 ± 10.362.2 ± 10.361.4 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPregabalin 300 mg/DayPregabalin 600 mg/DayTotal
Female32321377
Male10310232237
Region of Enrollment
Region of Enrollment(participants)PlaceboPregabalin 300 mg/DayPregabalin 600 mg/DayTotal
Japan13513445314
08

Study locations

49 sites
  • Pfizer Investigational Site
    Nagoya, Aichi, Japan
  • Pfizer Investigational Site
    Chikushino, Fukuoka, Japan
  • Pfizer Investigational Site
    Kasuga, Fukuoka, Japan
  • Pfizer Investigational Site
    Date-shi, Fukushima, Japan
  • Pfizer Investigational Site
    Nihonmatsu, Fukushima, Japan
  • Pfizer Investigational Site
    Shirakawa-shi, Fukushima, Japan
  • Pfizer Investigational Site
    Sukagawa, Fukushima, Japan
  • Pfizer Investigational Site
    Kure, Hiroshima, Japan
  • Pfizer Investigational Site
    Chitose, Hokkaido, Japan
  • Pfizer Investigational Site
    Ebetu, Hokkaido, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaiido, Japan
  • Pfizer Investigational Site
    Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Inashiki, Ibaraki, Japan
  • Pfizer Investigational Site
    Kamakura, Kanagawa, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Yatsushiro, Kumamoto, Japan
  • Pfizer Investigational Site
    Sendai, Miyagi, Japan
  • Pfizer Investigational Site
    Matsumoto, Nagano, Japan
  • Pfizer Investigational Site
    Ueda, Nagano, Japan
  • Pfizer Investigational Site
    Beppu, Oita, Japan
  • Pfizer Investigational Site
    Yamada, Okayama, Japan
  • Pfizer Investigational Site
    Naha, Okinawa, Japan
  • Pfizer Investigational Site
    Tomishiro, Okinawa, Japan
  • Pfizer Investigational Site
    Urazoe, Okinawa, Japan
  • Pfizer Investigational Site
    Higashiosaka, Osaka, Japan
  • Pfizer Investigational Site
    Hirano-ku, Osaka, Japan
  • Pfizer Investigational Site
    Kishiwada, Osaka, Japan
  • Pfizer Investigational Site
    Suminoe-ku, Osaka, Japan
  • Pfizer Investigational Site
    Sunto-gun, Shizuoka, Japan
  • Pfizer Investigational Site
    Oyama-shi, Tochigi, Japan
  • Pfizer Investigational Site
    Utsunomiya, Tochigi, Japan
  • Pfizer Investigational Site
    Arakawa, Tokyo, Japan
  • Pfizer Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Chiyoda-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Chuo-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Nishitokyo, Tokyo, Japan
  • Pfizer Investigational Site
    Ohta-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shibuya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
  • Pfizer Investigational Site
    Kumamoto, Japan
  • Pfizer Investigational Site
    Nagasaki, Japan
  • Pfizer Investigational Site
    Niigata, Japan
  • Pfizer Investigational Site
    Oita, Japan
  • Pfizer Investigational Site
    Okayama, Japan
  • Pfizer Investigational Site
    Saga, Japan
  • Pfizer Investigational Site
    Saitama, Japan
  • Pfizer Investigational Site
    Tokushima, Japan
09

References and documents

Publications

  • Alexander J Jr, Edwards RA, Manca L, Grugni R, Bonfanti G, Emir B, Whalen E, Watt S, Brodsky M, Parsons B. Integrating Machine Learning With Microsimulation to Classify Hypothetical, Novel Patients for Predicting Pregabalin Treatment Response Based on Observational and Randomized Data in Patients With Painful Diabetic Peripheral Neuropathy. Pragmat Obs Res. 2019 Oct 31;10:67-76. doi: 10.2147/POR.S214412. eCollection 2019. PubMed 31802967 ↗
  • Alexander J Jr, Edwards RA, Brodsky M, Manca L, Grugni R, Savoldelli A, Bonfanti G, Emir B, Whalen E, Watt S, Parsons B. Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. PLoS One. 2018 Dec 6;13(12):e0207120. doi: 10.1371/journal.pone.0207120. eCollection 2018. Erratum In: PLoS One. 2019 Feb 26;14(2):e0212959. doi: 10.1371/journal.pone.0212959. PubMed 30521533 ↗
  • Edwards RA, Bonfanti G, Grugni R, Manca L, Parsons B, Alexander J. Predicting Responses to Pregabalin for Painful Diabetic Peripheral Neuropathy Based on Trajectory-Focused Patient Profiles Derived from the First 4 Weeks of Treatment. Adv Ther. 2018 Oct;35(10):1585-1597. doi: 10.1007/s12325-018-0780-3. Epub 2018 Sep 11. PubMed 30206821 ↗
  • Parsons B, Li C, Emir B, Vinik AI. The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2018 Nov;34(11):2015-2022. doi: 10.1080/03007995.2018.1509304. Epub 2018 Sep 20. PubMed 30084288 ↗
  • Markman JD, Jensen TS, Semel D, Li C, Parsons B, Behar R, Sadosky AB. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017 Jul;17(6):718-728. doi: 10.1111/papr.12516. Epub 2016 Dec 1. PubMed 27611736 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2007
First posted
Nov 4, 2007
Start
Oct 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jun 22, 2010
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00553475
Responsible party
Sponsor
First posted
Nov 4, 2007
Start date
Oct 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jun 22, 2010
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion